Low‐gluten,nontransgenic wheat engineered with CRISPR/Cas9

Coeliac disease is an autoimmune disorder triggered in genetically predisposed individuals by the ingestion of gluten proteins from wheat, barley and rye. The α‐gliadin gene family of wheat contains four highly stimulatory peptides, of which the 33‐mer is the main immunodominant peptide in patients with coeliac. We designed two sgRNAs to target a conserved region adjacent to the coding sequence for the 33‐mer in the α‐gliadin genes. Twenty‐one mutant lines were generated, all showing strong reduction in α‐gliadins. Up to 35 different genes were mutated in one of the lines of the 45 different genes identified in the wild type, while immunoreactivity was reduced by 85%. Transgene‐free lines were identified, and no off‐target mutations have been detected in any of the potential targets. The low‐gluten, transgene‐free wheat lines described here could be used to produce low‐gluten foodstuff and serve as source material to introgress this trait into elite wheat varieties.     

基于CRISPR/Cas9的激活系统研究进展

基因编辑技术自问世以来就一直作为生物技术领域的研究热点。基因编辑工具成簇的规律间隔短回文重复序列及其相关系统(CRISPR/Cas系统)具有特异性、简便性和灵活性等优点,为研究人员提供了丰富的遗传操作工具,也让CRISPR/Cas系统的应用在多种生物中得到了飞速发展。特别是将转录激活因子与失活的Cas蛋白结合,可在RNA转录水平实现基因表达特异性调控,为生物技术在医学研究及农业领域的发展做出了重要的贡献。外源基因的过表达是验证基因功能和基因调控的常用方法,然而由于载体容量的限制难以实现多基因过表达。基于CRISPR/Cas9激活系统可在不同向导RNA的引导下对多个基因进行调控,实现调控水平验证基因功能。本文通过对CRISPR/Cas9激活系统组成及不同激活策略进行总结,整理针对过度激活的解决方案,为CRISPR/Cas9激活系统应用于棉花遗传改良及除草剂抗性研究提供更多参考。     

利用CRISPR/Cas9敲除人源细胞系中LMNA基因的研究

LMNA基因编码A型和C型核纤层蛋白,参与细胞核核膜的组织,影响基因组稳定性并对细胞分化产生影响。人类肿瘤中LMNA表达异常普遍存在,其突变造成多种核纤层蛋白病,如Emery-Dreifuss肌营养不良症(Emery-Dreifussmusculardystrophy,EDMD)、扩张型心肌病(dilatedcardiomyopathy,DCM)和儿童早老症(Hutchinson-Glifordprogeriasyndrome,HGPS)等。为进一步研究LMNA在细胞内的功能,本研究利用CRISPR/Cas9技术对体外培养的293T与HepG2细胞株的LMNA基因进行编辑,获得两株LMNA基因敲除(LMNA KO)的稳定细胞系。与野生型相比,LMNAKO细胞系增殖能力相对减弱,凋亡增加。同时,细胞形态上也发生显著改变,核膜凹凸不平。本研究首次报道了LMNA KO永生细胞系构建和形态研究结果,为后续LMNA基因功能研究和致病突变体研究奠定基础。     

应用CRISPR/Cas9技术构建YOD1基因敲除小鼠

目的:应用CRISPR/Cas9技术构建去泛素化酶YOD1基因敲除小鼠。方法:针对YOD1基因设计单链向导RNA(sg RNA)识别序列,构建sg RNA质粒,与Cas9质粒体外转录、纯化后注射入受精卵,通过PCR和测序验证得到F0代阳性小鼠。配繁两代后,取同窝对照的野生型(WT)和敲除(KO)小鼠的主要组织器官研磨,使用免疫印迹(WB)技术检测各组织YOD1蛋白的表达,确证YOD1敲除小鼠模型是否成功建立。统计YOD1杂合子(HET)自交存活后代各基因型比例,分析是否有胚胎致死表型。解剖小鼠分析主要组织器官的表型,进一步利用H.E.染色分析KO小鼠是否存在自发的病理改变。通过血糖耐受实验(GTT)分析KO小鼠的血糖调控能力。结果:基因组测序和WB检测结果显示KO小鼠中YOD1被明显敲除,YOD1敲除小鼠模型成功建立。YOD1杂合子自交后代各基因型比例符合孟德尔定律,提示KO小鼠非胚胎致死。YOD1敲除小鼠肝脏显著小于WT小鼠。GTT结果表明敲除YOD1不影响小鼠的血糖稳态。结论:应用CRISPR/Cas9技术成功构建YOD1基因敲除小鼠。KO小鼠正常出生,无任何胚胎发育缺陷。与WT小鼠相比,KO小鼠肝脏显著减小,但无显著的自发病理变化,KO小鼠血糖控制亦无显著差异。     

Application of protoplast technology to CRISPR/Cas9 mutagenesis: from single‐cell mutation detection to mutant plant regeneration

Plant protoplasts are useful for assessing the efficiency of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR‐associated protein 9 (Cas9) mutagenesis. We improved the process of protoplast isolation and transfection of several plant species. We also developed a method to isolate and regenerate single mutagenized Nicotianna tabacum protoplasts into mature plants. Following transfection of protoplasts with constructs encoding Cas9 and sgRNAs, target gene DNA could be amplified for further analysis to determine mutagenesis efficiency. We investigated N. tabacum protoplasts and derived regenerated plants for targeted mutagenesis of the phytoene desaturase (NtPDS) gene. Genotyping of albino regenerants indicated that all four NtPDS alleles were mutated in amphidiploid tobacco, and no Cas9 DNA could be detected in most regenerated plants.     

Study on the function of Helicoverpa armigera Wnt1 gene using CRISPR/Cas9 system

The Wnt signaling pathway, as a highly conserved signaling pathway in evolution, plays an important role in many biological processes. The research of Wnt signaling pathway through gene editing has been implemented in a variety of organisms. Among the various genome editing tools available for functional genomic research, CRISPR is popular because of its ease of use and versatility. Here, we use the CRISPR/Cas9 system to knock out the HaWnt1 gene of the important agricultural pest Helicoverpa armigera to explore the impacts on embryo development. Direct injection of Cas9 protein and Wnt1-specific single guide RNA (sgRNA) into H. armigera embryos successfully induced Wnt1 gene deletion mutants, which showed high lethality, abnormal segmentation, defected appendages and defected pigmentation. qRT-PCR analysis revealed that the deletion of Wnt1 gene affected the expression of several genes, which were closely related to the growth and development of insects. Our results indicate that HaWnt1 signaling pathway is essential for embryonic development of H. armigera. The study of the function of HaWnt1 gene not only lays the foundation for the study of the somatic development pattern of H. armigera, but also provides a candidate gene for genetic control of H. armigera.     

CRISPR/Cas9系统在昆虫中的应用

CRISPR/Cas9(clustered regularly interspaced short palindromic repeat/CRISPR-associated nuclease 9)技术是一种RNA引导的基因组靶向编辑技术,能对基因组序列进行精确编辑,在探究基因功能、修复受损基因、沉默有害基因、改良品质性状等方面具有广阔的应用前景。近年来,随着对CRISPR/Cas9系统研究的不断深入和改造,该系统以其操作简易、省时、高效等优点在生物学研究的众多领域中得以推广和应用,特别是在果蝇(Bombyx mori)、家蚕(silkworm)、埃及伊蚊(Aedes aegypti)和蝴蝶(butterfly)等多种昆虫中。本文概述了CRISPR/Cas9的结构、作用原理及发展优化,总结了CRISPR/Cas9导入昆虫的策略和在昆虫中的应用,以及对CRISPR/Cas9系统产生脱靶问题的应对策略,以期对经济昆虫和有益昆虫的分子育种、害虫的生物技术防控等研究提供参考。     

利用CRISPR/Cas9系统构建稳定敲除TrxR1基因的HCT-116细胞株北大核心CSCD

为更好地研究靶向硫氧还蛋白还原酶1的小分子化合物的细胞内靶点选择性,利用CRISPR/Cas9系统构建稳定敲除TrxR1基因(编码硫氧还蛋白还原酶1)的HCT-116细胞株。首先根据TrxR1基因序列和CRISPR/Cas9靶点设计原则,设计并选择合适的敲除位点,再根据敲除位点序列设计敲除TrxR1基因的sgRNA干扰序列,以pCasCMV-Puro-U6空质粒载体为骨架构建能表达该sgRNA干扰序列的重组质粒。质粒共转染至HCT-116细胞后,利用嘌呤霉素筛选TrxR1敲除的HCT-116细胞,通过DNA测序、免疫蛋白印迹、TRFS-green荧光探针和细胞内TrxR1酶活力检测等方法鉴定和验证HCT-116细胞的TrxR1基因敲除效果。进一步通过CCK-8实验初步研究靶向TrxR1小分子化合物对细胞内TrxR1酶活力和细胞增殖力抑制的相关性。结果显示,表达sgRNA干扰序列的重组质粒可以敲除HCT-116细胞中TrxR1基因,筛选获得的稳定敲除细胞HCT116-TrxR1-KO中无TrxR1蛋白表达,而靶向TrxR1小分子抑制剂对该细胞无TrxR1酶活力和细胞增殖力抑制效果。本研究利用CRISPR/Cas9系统成功构建了HCT-116的TrxR1基因敲除的稳定细胞株,为进一步研究TrxR1在相关疾病的发生机制和治疗中的作用奠定了基础。     

应用CRISPR/Cas9系统构建MTHFD1基因敲除的HEK-293细胞系

目的:利用成簇的、规律间隔的短回文重复序列/Cas9核酸酶(CRISPR/Cas9)基因编辑技术构建亚甲基四氢叶酸脱氢酶1(methylenetetrahydrofolate dehydrogenase 1, MTHFD1))基因敲除人胚肾(HEK-293)稳定细胞系。方法:利用在线软件筛选出评分最高的3条针对MTHFD1基因的单向导RNA (sg RNA),然后合成sg RNA序列并将其插入到含有GFP标签的质粒中;重组质粒转染HEK-293细胞后通过流式细胞仪分选出已被转入sg RNA的单细胞,通过测序确认单克隆细胞系中MTHFD1的DNA序列突变状态;最后应用实时荧光定量多聚核苷酸链式反应(real-time quantitative Polymerase Chain Reaction, RT-q PCR)和蛋白质印迹(Western blot)方法检测单克隆细胞中MTHFD1的m RNA和蛋白表达水平。结果:重组载体中含有正确的sg RNA序列;测序结果显示该细胞系中MTHFD1基因发生了单个碱基插入突变和6个碱基的缺失突变;RT-qPCR结果显示单克隆细胞系中MTHFD1在m RNA水平显著降低;Western blot检测成功构建MTHFD1蛋白缺失的HEK-293细胞。结论:本研究利用CRISPR/Cas9技术成功构建的MTHFD1敲除HEK-293细胞系。     

CRISPR/Cas9技术在工业微生物中的应用

近年来,通过基因编辑技术对工业微生物底盘细胞改造从而获得的优良细胞工厂,促进了农业、医学、环境、能源等领域的可持续发展,提高了人民的生活水平。微生物底盘细胞的改造离不开基因编辑,作为现阶段主要的基因编辑技术,规律间隔成簇短回文重复序列（clustered regularly interspaced short palindromic repeats,CRISPR）/Cas9系统自被发现以来,依靠其低成本、高效率等编辑优点,被广泛用于工业微生物底盘细胞的改造。本文主要简述了以CRISPR/Cas9为基础而衍伸出的各种基因编辑技术,提出了常用的工业微生物对应底盘细胞的改造策略,以期为研究者在进行微生物底盘细胞改造时选择出合适的基因编辑方法。最后指出了CRISPR基因编辑技术面临的PAM位点的依赖性、脱靶效应和应用广泛性等问题。     

Functional analysis of Bombyx Wnt1 during embryogenesis using the CRISPR/Cas9 system

Recently established, custom-designed nuclease technologies such as the clustered regularly interspaced short palindromic repeat (CRISPR)-associated system provide attractive genome editing tools. Targeted gene mutagenesis using the CRISPR/Cas9 system has been achieved in several orders of insects. However, outside of studies on Drosophila melanogaster and the lepidopteron model insect Bombyx mori, little success has been reported, which is largely due to a lack of effective genetic manipulation tools that can be used in other insect orders. To create a simple and effective method of gene knockout analysis, especially for dissecting gene functioning during insect embryogenesis, we performed a functional analysis of the Bombyx Wnt1 (BmWnt1) gene using Cas9/sgRNA-mediated gene mutagenesis. The Wnt1 gene is required for embryonic patterning in various organisms, and its crucial roles during embryogenesis have been demonstrated in several insect orders. Direct injection of Cas9 mRNA and BmWnt1-specific sgRNA into Bombyx embryos induced a typical Wnt-deficient phenotype: injected embryos could not hatch and exhibited severe defects in body segmentation and pigmentation in a dose-dependent manner. Quantitative real-time PCR (qRT-PCR) analysis revealed that Hox genes were down-regulated after BmWnt1 depletion. Furthermore, large deletion, up to 18 Kb, ware generated. The current study demonstrates that using the CRISPR/Cas9 system is a promising approach to achieve targeted gene mutagenesis during insect embryogenesis.     

CRISPR/Cas9 system in Plasmodium falciparum using the centromere plasmid

The CRISPR/Cas9 nuclease system is a powerful method to genetically modify the human malarial parasite, Plasmodium falciparum. Currently, this method is carried out by co-transfection with two plasmids, one containing the Cas9 nuclease gene, and another encoding the sgRNA and the donor template DNA. However, the efficiency of modification is currently low owing to the low frequency of these plasmids in the parasites. To improve the CRISPR/Cas9 nuclease system for P. falciparum, we developed a novel method using the transgenic parasite, PfCAS9, which stably expresses the Cas9 nuclease using the centromere plasmid. To examine the efficiency of genetic modification using the PfCAS9 parasite, we performed site-directed mutagenesis of kelch13 gene, which is considered to be involved in artemisinin resistance. Our results demonstrated that the targeted mutation could be introduced with almost 100% efficiency when the transfected PfCAS9 parasites were treated with two drugs to maintain both the centromere plasmid containing the Cas9 nuclease and the plasmid having the sgRNA. Therefore, the PfCAS9 parasite is a useful parasite line for the genetic modification of P. falciparum.     

Fast and cloning‐free CRISPR/Cas9‐mediated genomic editing in mammalian cells

CHoP‐In (CRISPR/Cas9‐mediated Homology‐independent PCR‐product integration) is a fast, non‐homologous end‐joining based, strategy for genomic editing in mammalian cells. There is no requirement for cloning in generation of the integration donor, instead the desired integration donor is produced as a polymerase chain reaction (PCR) product, flanked by the Cas9 recognition sequences of the target locus. When co‐transfected with the cognate Cas9 and guide RNA, double strand breaks are introduced at the target genomic locus and at both ends of the PCR product. This allows incorporation into the genomic locus via hon‐homologous end joining. The approach is versatile, allowing N‐terminal, C‐terminal or internal tag integration and gives predictable genomic integrations, as demonstrated for a selection of well characterised membrane trafficking proteins. The lack of donor vectors offers advantages over existing methods in terms of both speed and hands‐on time. As such this approach will be a useful addition to the genome editing toolkit of those working in mammalian cell systems.     

A justice‐based argument for including sickle cell disease in CRISPR/Cas9 clinical research

CRISPR/Cas9 is quickly becoming one of the most influential biotechnologies of the last five years. Clinical trials will soon be underway to test whether CRISPR/Cas9 can edit away the genetic mutations that cause sickle cell disease (SCD). This article will present the background of CRISPR/Cas9 gene editing and SCD, highlighting research that supports the application of CRISPR/Cas9 to SCD. While much has been written on why SCD is a good biological candidate for CRISPR/Cas9, less has been written on the ethical implications of including SCD in CRISPR/Cas9 research. This article will argue that there is a strong case in favor of including SCD. Three benefits are achieving distributive justice in research, continuing to repair the negative relationship between patients with SCD and the health‐care system, and benefit‐sharing for those who do not directly participate in CRISPR/Cas9 research. Opponents will argue that SCD is a risky candidate, that researchers will not find willing participants, and that the burden of SCD is low. Of this set of arguments, the first gives pause. However, on balance, the case in favor of including SCD in CRISPR/Cas9 research is stronger than the case against. Ultimately, this article will show that the historic and sociopolitical injustices that impede progress in treating and curing SCD can be alleviated through biotechnology.